TY - JOUR
T1 - A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients
AU - Kida, Daihei
AU - Takahashi, Nobunori
AU - Kaneko, Atsushi
AU - Hirano, Yuji
AU - Fujibayashi, Takayoshi
AU - Kanayama, Yasuhide
AU - Hanabayashi, Masahiro
AU - Yabe, Yuichiro
AU - Takagi, Hideki
AU - Oguchi, Takeshi
AU - Kato, Takefumi
AU - Funahashi, Koji
AU - Matsumoto, Takuya
AU - Ando, Masahiko
AU - Kuwatsuka, Yachiyo
AU - Tanaka, Eiichi
AU - Yasuoka, Hidekata
AU - Kaneko, Yuko
AU - Hirata, Shintaro
AU - Murakami, Kosaku
AU - Sobue, Yasumori
AU - Nishiume, Tsuyoshi
AU - Suzuki, Mochihito
AU - Yokota, Yutaka
AU - Terabe, Kenya
AU - Asai, Shuji
AU - Ishiguro, Naoki
AU - Kojima, Toshihisa
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12
Y1 - 2020/12
N2 - This study aimed to evaluate the effectiveness of abatacept (ABA) by anti-cyclic citrullinated peptide (ACPA) status on disease activity as well as radiographic progression in patients with rheumatoid arthritis (RA) in clinical settings. A retrospective cohort study was conducted using data from a multicenter registry. Data from a total of 553 consecutive RA patients treated with intravenous ABA were included. We primarily compared the status of disease activity (SDAI) and radiographic progression (van der Heijde modified total Sharp score: mTSS) between the ACPA-negative (N = 107) and ACPA-positive (N = 446) groups. ‘ACPA positive’ was defined as ≥ 13.5 U/mL of anti-CCP antibody. Baseline characteristics between groups were similar. The proportion of patients who achieved low disease activity (LDA; SDAI ≤ 11) at 52 weeks was significantly higher in the ACPA-positive group. Multivariate logistic regression analysis identified ACPA positivity as an independent predictor for achievement of LDA at 52 weeks. Drug retention rate at 52 weeks estimated by the Kaplan–Meier curve was significantly higher in the ACPA-positive group. Achievement rate of structural remission (ΔmTSS ≤ 0.5) at 52 weeks was similar between groups. ABA treatment demonstrated a significantly higher clinical response and higher drug retention rate in ACPA-positive patients. Progression of joint destruction was similar between the ACPA-negative and ACPA-positive groups. Close attention should be paid to joint destruction even in patients showing a favorable response to ABA, especially when the ACPA status is positive.
AB - This study aimed to evaluate the effectiveness of abatacept (ABA) by anti-cyclic citrullinated peptide (ACPA) status on disease activity as well as radiographic progression in patients with rheumatoid arthritis (RA) in clinical settings. A retrospective cohort study was conducted using data from a multicenter registry. Data from a total of 553 consecutive RA patients treated with intravenous ABA were included. We primarily compared the status of disease activity (SDAI) and radiographic progression (van der Heijde modified total Sharp score: mTSS) between the ACPA-negative (N = 107) and ACPA-positive (N = 446) groups. ‘ACPA positive’ was defined as ≥ 13.5 U/mL of anti-CCP antibody. Baseline characteristics between groups were similar. The proportion of patients who achieved low disease activity (LDA; SDAI ≤ 11) at 52 weeks was significantly higher in the ACPA-positive group. Multivariate logistic regression analysis identified ACPA positivity as an independent predictor for achievement of LDA at 52 weeks. Drug retention rate at 52 weeks estimated by the Kaplan–Meier curve was significantly higher in the ACPA-positive group. Achievement rate of structural remission (ΔmTSS ≤ 0.5) at 52 weeks was similar between groups. ABA treatment demonstrated a significantly higher clinical response and higher drug retention rate in ACPA-positive patients. Progression of joint destruction was similar between the ACPA-negative and ACPA-positive groups. Close attention should be paid to joint destruction even in patients showing a favorable response to ABA, especially when the ACPA status is positive.
UR - http://www.scopus.com/inward/record.url?scp=85095955045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095955045&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-76842-4
DO - 10.1038/s41598-020-76842-4
M3 - Article
C2 - 33184461
AN - SCOPUS:85095955045
SN - 2045-2322
VL - 10
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 19717
ER -